Urologic Oncology Research Training Grant

 描述（由申请人提供）：自1999年成立以来，纪念斯隆-凯特琳癌症中心（MSKCC）的T32泌尿肿瘤研究培训计划的主要目标是培训选定的泌尿科医生从事泌尿肿瘤转化研究的生产性职业。泌尿肿瘤学的专门研究培训对国家癌症研究所（NCI）降低泌尿生殖系统癌症发病率和死亡率的使命至关重要，泌尿生殖系统癌症占美国所有癌症相关死亡的10%左右，预计随着人口老龄化，其发病率将稳步上升。自1973年以来，MSKCC是一家NCI指定的综合性癌症中心，为临床医生-科学家的培训提供了一流的环境和许多独特的资源，包括大量的患者， 所有类型和阶段的泌尿系统恶性肿瘤、具有长期临床随访的大型临床数据库、具有血液样本的大型新鲜肿瘤库以及尖端的基础和转化科学研究项目。MSKCC的T32泌尿肿瘤学研究培训计划旨在利用这些独特的研究培训机会。在拟议的资助期间，新的项目主任和T32委员会制定了一个互动的、多学科的研究培训战略，其中包括：（1）基础，临床和翻译研究人员的多学科学院，涵盖外科，分子药理学和化学，医学，癌症生物学和遗传学，分子放射学，生物统计学和流行病学以及实验室医学，（2）根据T32学员的研究兴趣和目标量身定制的强化指导研究实习，（3）必要的教学和讨论为基础的课程的核心课程，以提高实践研究培训的质量，（4）在赠款写作和职业发展奖励方面的结构化职业发展研讨会，及（5）选修活动，让T32学员进一步沉浸在癌症研究的世界，并与同行和知名领导者建立联系。每年，2名来自MSKCC泌尿肿瘤学奖学金计划的高度敬业的博士后学员被选为T32泌尿肿瘤学研究培训计划。他们必须拥有医学博士学位，必须完成泌尿外科住院医师培训，并且必须是符合董事会资格的泌尿科医生。这2名学员在2年内获得T32培训补助金的支持，专门用于泌尿肿瘤学研究培训，并根据适当的进展任命为第二年。在完成培训后，T32泌尿肿瘤学研究培训计划的毕业生有望成为以研究为重点的学术组织的初级教师职位的有吸引力的候选人。在过去的5年中，88%的T32实习生毕业生被学术机构录取，并从事旨在了解和克服泌尿生殖系统癌症的实验室和/或临床研究。

 DESCRIPTION (provided by applicant): Since its inception in 1999, the primary objective of the T32 Urologic Oncology Research Training Program at Memorial Sloan Kettering Cancer Center (MSKCC) has been to train select urologists for productive careers in translational research in urologic oncology. Dedicated research training in urologic oncology is essential to the mission of the National Cancer Institute (NCI) to reduce morbidity and mortality from genitourinary cancers, which cause about 10% of all cancer-related deaths in the United States and which are expected to rise steadily in incidence as the population ages. An NCI-designated comprehensive cancer center since 1973, MSKCC provides a first-class environment with many unique resources for the training of clinician-scientists, including a high volume of patients with all types and stages of urologic malignancies, large clinical databases with long-term clinical follow-up, large fresh tumor banks with blood samples, and cutting-edge basic and translational scientific research programs. The T32 Urologic Oncology Research Training Program at MSKCC has been designed to capitalize on these unique research training opportunities. For the proposed funding period, the new Program Director and T32 Committee have developed an interactive, multidisciplinary research training strategy that integrates the following: (1) a multidisciplinary faculty of basic, clinical, and translational researchers spanning the discipline of surgery, molecular pharmacology and chemistry, medicine, cancer biology and genetics, molecular radiology, biostatistics and epidemiology, and laboratory medicine, (2) an intensive mentored research practicum tailored to the T32 trainee's research interests and goals, (3) a core curriculum of required didactic and discussion-based courses to enhance the quality of the hands- on research training, (4) structured career development workshops in grant writing and career development awards, and (5) elective activities that will allow T32 trainees to further immerse themselves in the world of cancer research and to network with peers and established leaders. Each year, 2 highly committed postdoctoral trainees from the Urologic Oncology Fellowship Program at MSKCC are selected for the T32 Urologic Oncology Research Training Program. They must have an MD, must have completed residency training in urology, and must be board-eligible urologists. These 2 trainees are supported by this T32 training grant during 2 years dedicated to urologic oncology research training, with appointment to the 2nd year contingent on suitable progress. At the completion of their training, graduates of theT32 Urologic Oncology Research Training Program are expected to be attractive candidates for junior faculty appointments at research-focused academic organizations. In the past 5 years, 88% of T32 trainee graduates have matriculated to faculty positions at academic institutions and are engaged in laboratory and/or clinical research aimed at understanding and overcoming genitourinary cancers.